Sector Experts

Greg Wade

Wedbush

Greg Wade, managing director and senior analyst with Wedbush Securities, has worked on the sellside since early 2000, first at Pacific Growth Equities and subsequently at Wedbush PacGrow LifeSciences, where he was promoted to managing director in 2011. Wade's coverage of emerging biopharmaceutical companies is supported by analyst team members David Nierengarten and Chris Marai. Wade earned an undergraduate degree with honors in medical biophysics and a doctorate in physiology from the University of Western Ontario in London, Canada.




Recent Interviews

Wedbush Expert Declares Money for Biotech Is Still Out There (8/8/13) medsymbol82The bull market in biotech stocks is coming up on its two-year anniversary, and large-cap and many small-cap names have flourished in that time. But can it last? Greg Wade, managing director of Wedbush Securities, wants investors to know there's more to go, and that stocks are ready and willing to respond to good news from clinical trials and on the regulatory front. In this interview with The Life Sciences Report, Wade identifies six names that investors can take to the bank, one of which is still his favorite after two years.

Eight Biotech Growth Names: Greg Wade (2/7/13) wadesub82The driving principle behind successful biotech investment for Managing Director and Senior Analyst Greg Wade of Wedbush Securities is to find companies with clinical assets that are of value to patients and hence to the marketplace. In this interview with The Life Sciences Report, Wade offers compelling cases for eight important names that span the market cap gamut.

Analyst Bets on Extraordinary Science and Clinical Data: Greg Wade (8/30/12) Managing Director Greg Wade of Wedbush Securities doesn't use a cookie-cutter approach to picking biotechnology stocks. He directs investors to companies with strong science, well-executed clinical studies and data that point toward future success. In this exclusive interview with The Life Sciences Report, Wade shares his favorite names and the compelling stories behind each company.

Recent Quotes

"There are quite a few catalysts in H2/13 for ONCY." (8/8/13) Oncolytics Biotech Inc. - The Life Sciences Report Interview with Greg Wade More >

"We reiterate our Outperform rating on ONCY." (8/1/13) Oncolytics Biotech Inc. - Greg Wade, Wedbush More >

"Expect ONCY's stock to move sharply after positive data from cancer studies." (3/19/13) Oncolytics Biotech Inc. - Greg Wade, Wedbush More >

"We reiterate our Outperform rating on OGXI." (3/11/13) OncoGenex Pharmaceuticals Inc. - Greg Wade, Wedbush More >

"We continue to be encouraged by the potential for ONCY's drug and are very eager to see how this phase 3 study turns out." (2/7/13) Oncolytics Biotech Inc. - The Life Sciences Report Interview with Greg Wade More >

"We are maintaining our Outperform rating for OGXI." (12/19/12) OncoGenex Pharmaceuticals Inc. - Greg Wade, Wedbush More >

"We reiterate our Outperform rating for ONC." (12/13/12) Oncolytics Biotech Inc. - Greg Wade, Wedbush More >

"We are maintaining our Outperform rating on OGXI." (11/9/12) OncoGenex Pharmaceuticals Inc. - Greg Wade, Wedbush More >

more comments

"We are maintaining our Outperform rating on OGXI." (9/19/12) OncoGenex Pharmaceuticals Inc. - Greg Wade, Wedbush More >

"Our survey revealed if OGXI's Custirsen were to show an overall survival benefit, 95% of physicians would use it." (9/19/12) OncoGenex Pharmaceuticals Inc. - Greg Wade, Wedbush More >

fewer comments


Due to permission requirements, not all quotes are shown.